2 completed, 2 recruiting, 1 available, 1 withdrawn. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 2, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow 60 Degrees Pharmaceuticals LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| B-FREE Chronic Babesiosis Study Tafenoquine 100mg - Chronic Babesiosis | Phase 2 | Recruiting | 60 Degrees Pharmaceuticals LLC | 40 | 2025-11-18 | 2025-11-21 |
| Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis Tafenoquine, Placebo - Babesiosis | Phase 2 | Recruiting | 60 Degrees Pharmaceuticals LLC | 33 | 2024-06-17 | 2025-11-21 |
| Tafenoquine in Patients With Mild to Moderate COVID-19 Tafenoquine Oral Tablet, Placebo - COVID 19 Disease | Phase 2 | Completed | 60 Degrees Pharmaceuticals LLC | 86 | 2021-02-19 | 2025-01-07 |
| Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Celgosivir, Modipafant 50mg, Placebo - Dengue Fever | Phase 1 / Phase 2 | Withdrawn | Singapore General Hospital | 2018-12-01 | 2020-03-23 | |
| Long-Term Safety Study of Tafenoquine Tafenoquine, Placebo - Healthy Volunteers | Phase 2 | Completed | 60 Degrees Pharmaceuticals LLC | 600 | 2017-10-05 | 2026-04-17 |
| Expanded Use in Persistent (B. Microti) Babesiosis Tafenoquine - Persistent Babesiosis | Available | 60 Degrees Pharmaceuticals LLC | 2025-11-21 |
Babesiosis (1) · Communicable Diseases (1) · Dengue (1)
tafenoquine (5) · celgosivir (1) · modipafant (1)
United States (4) · Australia (1) · Singapore (1)
Akila Chandrasekar, MD (1) · Jenny Low, Dr (1)
PMID 16282461, PMID 22958431, PMID 26794905, PMID 32015507, PMID 32052514, PMID 32423584, PMID 32445440, PMID 32673060, PMID 34801714, PMID 9598455